Page last updated: 2024-08-16

raloxifene and su 11248

raloxifene has been researched along with su 11248 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Lao, K; Li, X; Luo, G; Tang, Z; Xiang, H; You, Q1
Cai, X; Li, X; Lin, X; Liu, L; Luo, G; Wu, C; Xiang, H; You, Q1

Reviews

1 review(s) available for raloxifene and su 11248

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

2 other study(ies) available for raloxifene and su 11248

ArticleYear
Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
    European journal of medicinal chemistry, 2018, Apr-25, Volume: 150

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Humans; Ligands; MCF-7 Cells; Molecular Structure; Neovascularization, Pathologic; Pyrimidines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2018
Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
    European journal of medicinal chemistry, 2019, Jan-01, Volume: 161

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Humans; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2019